Overview What We're Doing Researchers Clinical Trials & Partnerships Overview One of the greatest barriers to immunotherapy effectively working against solid tumors is the tumor microenvironment. Like the walls of an evil fortress, the tumor microenvironment acts like a barricade around cancer, walling it off from attack. When confronting this barrier, cancer-killing T-cells and checkpoint inhibitors ultimately fail. Even if they manage to breach the wall, the T-cells that enter the tumor undergo a chemical assault: the microenvironment is acidic, low in oxygen and full of toxins. What We’re Doing PICI investigators are testing new technologies to better understand and visualize how the tumor microenvironment is structured and how it functions. The more we know, the sooner we can knock down the walls and defeat the enemy. We’ve also forged a partnership with biotech company PsiOxus to develop novel therapies that can change the microenvironment, making it easier for cancer-killing immune cells to do their job: end cancer once and for all. Researchers Max Krummel, PhD Lewis Lanier, PhD Alexander Y. Rudensky, PhD Dmitriy Zamarin, MD, PhD Clinical Trials and Partnerships PsiOxus partnership Related Press Release PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors Cancer Research Heroes, Our Impact, Press Release The Parker Institute for Cancer Immunotherapy Expands its Network to Include More Rising Stars in Cancer Immunotherapy Research Update UCLA Study Shows Virus Plus Immunotherapy Hold Promise for Advanced Melanoma
Press Release PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors
Cancer Research Heroes, Our Impact, Press Release The Parker Institute for Cancer Immunotherapy Expands its Network to Include More Rising Stars in Cancer Immunotherapy